

## CARE Checklist of information to include when writing a case report





Abstract Abs	Topic	Item	Checklist item description	Reported on Line
Abstract (no references) 3a Infroduction: What is unique about this case and what does it add to the scientific literature? 59-64 (no references) 3b Main symptoms and/or important clinical findings 66 - 82 (The main diagnoses, therapeutic interventions, and outcomes 13d Conclusion—What is the main Take-away' lessons(s) from this case? 181-186 (Introduction 4 One or two paragraphs summarizing why this case is unique (may include references) 105-134 (Introduction 5b Primary concerns and symptoms of the patient. 66-67 (Medical, family, and psycho-social history including relevant genetic information 68-71 (Medical, family, and psycho-social history including relevant genetic information 17d (Medical, family, and psycho-social history including relevant genetic information 17d (Medical, family, and psycho-social history including relevant genetic information 17d (Medical, family, and psycho-social history including relevant genetic information 17d (Medical, family, and psycho-social history including relevant genetic information 17d (Medical, family, and psycho-social history) including relevant genetic information 17d (Medical, family, and psycho-social history) including relevant genetic information 17d (Medical, family, and psycho-social history) including relevant genetic information 17d (Medical, family, and psycho-social history) including relevant genetic information 17d (Medical) 17d (Medical, family, and psycho-social history) including relevant genetic information 17d (Medical) 17d 1	Title	1	The diagnosis or intervention of primary focus followed by the words "case report"	1-2
Main symptoms and/or important clinical findings   66 - 82	Key Words	2	2 to 5 key words that identify diagnoses or interventions in this case report, including "case report"	50
The main diagnoses, therapeutic interventions, and outcomes  3c The main diagnoses, therapeutic interventions, and outcomes  3c Onclusion—What is the main "take-away" lesson(s) from this case?  181-186  181-188  181-186  181-181  181-181  181-181  181-181  181-181  181-181  181-181  181-181  181-181  181-181  181-181  181-181  181-181  181-181  181-181	Abstract (no references)	3a	Introduction: What is unique about this case and what does it add to the scientific literature?	59-64
Introduction 4 One or two paragraphs summarizing why this case is unique (may include references) 105-134   Patient Information 5 De-identified patient specific information. 7/a   5 Primary concerns and symptoms of the patient. 66-67   5 Medical, family, and psycho-social history including relevant genetic information 7/a   68-71   68-71   68-71   74-72   68-73   68-74   74-80, 87-88   75 Medical, family, and psycho-social history including relevant genetic information 7/a   75 Medical, family, and psycho-social history including relevant genetic information 7/a   75 Medical, family, and psycho-social history including relevant genetic information 7/a   75 Medical, family, and psycho-social history including relevant genetic information 7/a   76 Medical, family, and psycho-social history including relevant genetic information 7/a   77 Medical and current information from this episode of care organized as a timeline 7/a   78 Diagnostic testing (such as PE, laboratory testing, imaging, surveys). 71-81   79 Diagnostic testing (such as PE, laboratory testing, imaging, surveys). 71-81   71-81   71-81   71-82   71-83   71-84   71-84   71-84   71-85   71-86   71-		3b	Main symptoms and/or important clinical findings	66 - 82
Patient Information Patien		3c	The main diagnoses, therapeutic interventions, and outcomes	83-152
Patient Information 5a De-identified patient specific information. 66-67 5b Primary concerns and symptoms of the patient. 66-67 5c Medical, family, and psycho-social history including relevant genetic information 68-71 5d Relevant past interventions with outcomes 71-80, 87-88 Iminical Findings 6 Describe significant physical examination (PE) and important clinical findings 71-80, 87-88 Imineline 7 Historical and current information from this episode of care organized as a timeline 74 Infesting Spannes 1 Spannes		3d	Conclusion—What is the main "take-away" lesson(s) from this case?	181-186
State   Primary concerns and symptoms of the patient.   66-67	ntroduction	4	One or two paragraphs summarizing why this case is unique (may include references)	105-134
Sc Medical, family, and psycho-social history including relevant genetic information 68-71  Sd Relevant past interventions with outcomes 71-80, 87-88  Initial Findings 6 Describe significant physical examination (PE) and important clinical findings. 71-80, 87-88  Imeline 7 Historical and current information from this episode of care organized as a timeline n/a  Iniagnostic 8a Diagnostic testing (such as PE, laboratory testing, imaging, surveys). 71-81  Initial 8b Diagnostic challenges (such as access to testing, financial, or cultural). n/a  8c Diagnosis (including other diagnoses considered). 84-134  8d Prognosis (such as staging in oncology) where applicable 151-152  Intervention 9b Administration of therapeutic intervention (such as pharmacologic, surgical, preventive, self-care) 136-151  Ollow-up and 10a Clinician and patient-assessed outcomes (if available). n/a  Intervention 10b Important follow-up diagnostic and other test results 145-152  Intervention 21c Intervention adherence and tolerability (How was this assessed?) 136-141  Intervention 21c Intervention adherence and tolerability (How was this assessed?) 136-141  Intervention 21c Intervention adherence and tolerability (How was this assessed?) 172-186  Intervention 21c Intervention adherence and tolerability (How was this assessed?) 178-197  Intervention 21c The scientific discussion of the strengths AND limitations associated with this case report (without references) 178-197  Intervention 21c Intervention adherence and tolerability with references 178-197  Intervention 21c Intervention adherence and tolerability with references in a one paragraph conclusion 201-204  Intervention 21c Intervention adherence and tolerability intervention assessment of possible causes) 205-208  Intervention 21c Intervention adherence and tolerability intervention assessment of possible causes) 205-208  Intervention 21c Intervention 21	Patient Information	5a	De-identified patient specific information	n/a
Statistical Findings		5b	Primary concerns and symptoms of the patient	66-67
Inical Findings imeline 7 Historical and current information from this episode of care organized as a timeline 17 Historical and current information from this episode of care organized as a timeline 18 Diagnostic (such as PE, laboratory testing, imaging, surveys). 18 Diagnostic challenges (such as access to testing, financial, or cultural) 18 Diagnosis (including other diagnoses considered). 18 Prognosis (such as staging in oncology) where applicable. 18 Prognosis (such as staging in oncology) where applicable. 18 Prognosis (such as staging in oncology) where applicable. 18 Prognosis (such as staging in oncology) where applicable. 18 Prognosis (such as staging in oncology) where applicable. 18 Prognosis (such as staging in oncology) where applicable. 18 Prognosis (such as staging in oncology) where applicable. 18 Prognosis (such as staging in oncology) where applicable. 18 Prognosis (such as staging in oncology) where applicable. 18 Prognosis (such as staging in oncology) where applicable. 18 Prognosis (such as staging in oncology) where applicable. 18 Prognosis (such as staging in oncology) where applicable. 18 Prognosis (such as staging in oncology) where applicable. 18 Prognosis (such as staging in oncology) where applicable. 18 Prognosis (such as staging in oncology) where applicable. 18 Prognosis (such as staging in oncology) where applicable. 18 Prognosis (such as access to testing, financial, or cultural) 18 Prognosis (such as access to testing, financial, or cultural) 18 Prognosis (such as access to testing, financial, or cultural) 18 Prognosis (such as access to testing, financial, or cultural) 18 Prognosis (such as access to testing, financial, or cultural) 18 Prognosis (such as access to testing, financial, or cultural) 18 Prognosis (such as access to testing, financial, or cultural) 18 Prognosis (such as access to testing, financial, or cultural) 18 Prognosis (such as access to testing, financial, or cultural) 18 Prognosis (such as access to testing, financial, or cultural) 19 Prognosis (such as acc		5c	Medical, family, and psycho-social history including relevant genetic information	68-71
ineline 7 Historical and current information from this episode of care organized as a timeline 7.1–81  plagnostic 18 Diagnostic testing (such as PE, laboratory testing, imaging, surveys). 7.1–81  plagnostic challenges (such as access to testing, financial, or cultural). 7.1–81  plagnosis (including other diagnoses considered). 84–134  prognosis (such as staging in oncology) where applicable 151–152  plagnosis (such as staging in oncology) where applicable 151–152  plagnosis (such as staging in oncology) where applicable 151–152  plagnosis (such as staging in oncology) where applicable 151–152  plagnosis (such as staging in oncology) where applicable 151–152  plagnosis (such as staging in oncology) where applicable 151–152  plagnosis (such as staging in oncology) where applicable 151–152  plagnosis (such as staging in oncology) where applicable 151–152  plagnosis (such as staging in oncology) where applicable 151–152  plagnosis (such as staging in oncology) where applicable 151–152  plagnosis (such as staging in oncology) where applicable 151–152  plagnosis (such as staging in oncology) where applicable 151–152  plagnosis (such as staging in oncology) where applicable 151–152  plagnosis (such as staging in oncology) where applicable 151–152  plagnosis (such as access to testing, financial, or cultural) 136–151  n/a  136–151  n/a  145–152  145–152  10c Changes in therapeutic intervention (such as dosage, strength, duration) n/a  11d Important follow-up diagnostic and other test results 145–152  11d Intervention adherence and tolerability (How was this assessed?) 136–141  11d A scientific discussion of the strengths AND limitations associated with this case report 172–186  11d The scientific rationale for any conclusions (including assessment of possible causes) 205–208  11d The primary "take-away" lessons of this case report (without references) in a one paragraph conclusion 201–204  149–150		5d	Relevant past interventions with outcomes	n/a
Diagnostic and cuterit lithoritation from this episode of called grantized as a timeline and provided as personal provided as a personal provided as personal provided as personal provided as access to testing, financial, or cultural).  8b Diagnostic challenges (such as access to testing, financial, or cultural).  8c Diagnosis (including other diagnoses considered).  8d Prognosis (such as staging in oncology) where applicable.  9a Types of therapeutic intervention (such as pharmacologic, surgical, preventive, self-care).  136-151  9b Administration of therapeutic intervention (such as dosage, strength, duration).  9c Changes in therapeutic intervention (with rationale).  10d Clinician and patient-assessed outcomes (if available).  10d Important follow-up diagnostic and other test results.  10d Intervention adherence and tolerability (How was this assessed?).  11d Ascientific discussion of the strengths AND limitations associated with this case report.  11d The scientific rationale for any conclusions (including assessment of possible causes).  205-208  11d The primary "take-away" lessons of this case report (without references) in a one paragraph conclusion.  201-204  149-150	linical Findings	6	Describe significant physical examination (PE) and important clinical findings	71-80, 87-88
Sampostic   Sampostic   Sampostic testing (such as PE, laboratory testing, imaging, surveys).   71-81   n/a   8b   Diagnostic challenges (such as access to testing, financial, or cultural)   n/a   84-134   84   85   Diagnosis (including other diagnoses considered)   151-152	imeline	7	Historical and current information from this episode of care organized as a timeline	n/a
Bb Diagnostic challenges (such as access to testing, financial, or cultural)  8c Diagnosis (including other diagnoses considered)  8d Prognosis (such as staging in oncology) where applicable  151-152  136-151  136-151  19b Administration of therapeutic intervention (such as pharmacologic, surgical, preventive, self-care)  136-151  17a  9c Changes in therapeutic intervention (such as dosage, strength, duration)  9c Changes in therapeutic intervention (with rationale)  10a Clinician and patient-assessed outcomes (if available)  10b Important follow-up diagnostic and other test results  10c Intervention adherence and tolerability (How was this assessed?)  11d Adverse and unanticipated events  11d A scientific discussion of the strengths AND limitations associated with this case report  11c The scientific rationale for any conclusions (including assessment of possible causes)  12d The patient should share their perspective in one to two paragraphs on the treatment(s) they received  149-150	Diagnostic Assessment	8a	·	71-81
Registering statements of the strengths and patient as staging in oncology) where applicable  151-152  136-151  136-151  136-151  136-151  136-151  136-151  136-151  136-151  136-151  136-151  136-151  136-151  136-151  145-152  145-152  145-152  10c Intervention adherence and tolerability (How was this assessed?)  116 Adverse and unanticipated events  136-141  100 Adverse and unanticipated events  136-141  11b Discussion of the strengths AND limitations associated with this case report  11c The scientific rationale for any conclusions (including assessment of possible causes)  12d The primary "take-away" lessons of this case report (without references) in a one paragraph conclusion  149-150  149-150		8b	Diagnostic challenges (such as access to testing, financial, or cultural)	n/a
Types of therapeutic intervention (such as pharmacologic, surgical, preventive, self-care)  9a Types of therapeutic intervention (such as dosage, strength, duration)  9b Administration of therapeutic intervention (such as dosage, strength, duration)  9c Changes in therapeutic intervention (with rationale)  10a Clinician and patient-assessed outcomes (if available)  10b Important follow-up diagnostic and other test results  10c Intervention adherence and tolerability (How was this assessed?)  10d Adverse and unanticipated events  11d A scientific discussion of the strengths AND limitations associated with this case report  11b Discussion of the relevant medical literature with references  11c The scientific rationale for any conclusions (including assessment of possible causes)  11d The primary "take-away" lessons of this case report (without references) in a one paragraph conclusion  201-204  149-150		8c	Diagnosis (including other diagnoses considered)	84-134
Administration of therapeutic intervention (such as dosage, strength, duration)  9c Changes in therapeutic intervention (with rationale)  10a Clinician and patient-assessed outcomes (if available)  10b Important follow-up diagnostic and other test results  10c Intervention adherence and tolerability (How was this assessed?)  10d Adverse and unanticipated events  11a A scientific discussion of the strengths AND limitations associated with this case report  11b Discussion of the relevant medical literature with references.  11c The scientific rationale for any conclusions (including assessment of possible causes)  11d The primary "take-away" lessons of this case report (without references) in a one paragraph conclusion  201-204  149-150		8d	Prognosis (such as staging in oncology) where applicable	151-152
9c Changes in therapeutic intervention (with rationale) 145-152  nollow-up and Putcomes 10b Important follow-up diagnostic and other test results 145-152  10c Intervention adherence and tolerability (How was this assessed?) 136-141  10d Adverse and unanticipated events 136-141  11d A scientific discussion of the strengths AND limitations associated with this case report 172-186  11b Discussion of the relevant medical literature with references 178-197  11c The scientific rationale for any conclusions (including assessment of possible causes) 205-208  11d The primary "take-away" lessons of this case report (without references) in a one paragraph conclusion 201-204  201-204  The patient Perspective 12 The patient should share their perspective in one to two paragraphs on the treatment(s) they received 149-150	Therapeutic Intervention	9a	Types of therapeutic intervention (such as pharmacologic, surgical, preventive, self-care)	136-151
Clinician and patient-assessed outcomes (if available).  10a Clinician and patient-assessed outcomes (if available).  10b Important follow-up diagnostic and other test results  10c Intervention adherence and tolerability (How was this assessed?).  10d Adverse and unanticipated events  11a A scientific discussion of the strengths AND limitations associated with this case report.  11b Discussion of the relevant medical literature with references.  11c The scientific rationale for any conclusions (including assessment of possible causes).  11d The primary "take-away" lessons of this case report (without references) in a one paragraph conclusion.  11d The patient should share their perspective in one to two paragraphs on the treatment(s) they received.  12 The patient should share their perspective in one to two paragraphs on the treatment(s) they received.		9b	Administration of therapeutic intervention (such as dosage, strength, duration)	n/a
10b Important follow-up diagnostic and other test results 10c Intervention adherence and tolerability (How was this assessed?) 11d Adverse and unanticipated events 11a A scientific discussion of the strengths AND limitations associated with this case report 11b Discussion of the relevant medical literature with references. 11c The scientific rationale for any conclusions (including assessment of possible causes) 11d The primary "take-away" lessons of this case report (without references) in a one paragraph conclusion 11d The patient should share their perspective in one to two paragraphs on the treatment(s) they received 149-150		9c	Changes in therapeutic intervention (with rationale)	145-152
10c Intervention adherence and tolerability (How was this assessed?)	Follow-up and Outcomes	10a	Clinician and patient-assessed outcomes (if available)	n/a
10d Adverse and unanticipated events 136-141  11a A scientific discussion of the strengths AND limitations associated with this case report 172-186  11b Discussion of the relevant medical literature with references 178-197  11c The scientific rationale for any conclusions (including assessment of possible causes) 205-208  11d The primary "take-away" lessons of this case report (without references) in a one paragraph conclusion 201-204  201-204  201-204		10b	Important follow-up diagnostic and other test results	145-152
11a A scientific discussion of the strengths AND limitations associated with this case report		10c	Intervention adherence and tolerability (How was this assessed?)	136-141
11b Discussion of the relevant medical literature with references. 178-197  11c The scientific rationale for any conclusions (including assessment of possible causes) 205-208  11d The primary "take-away" lessons of this case report (without references) in a one paragraph conclusion 201-204  Patient Perspective 12 The patient should share their perspective in one to two paragraphs on the treatment(s) they received 149-150		10d	Adverse and unanticipated events	136-141
The scientific rationale for any conclusions (including assessment of possible causes)	Discussion	11a	A scientific discussion of the strengths AND limitations associated with this case report	172-186
11d The primary "take-away" lessons of this case report (without references) in a one paragraph conclusion		11b	·	178-197
The primary "take-away" lessons of this case report (without references) in a one paragraph conclusion		11c	The scientific rationale for any conclusions (including assessment of possible causes)	205-208
Patient Perspective 12 The patient should share their perspective in one to two paragraphs on the treatment(s) they received		11d		201-204
	Patient Perspective	12	, , , , , , , , , , , , , , , , , , , ,	149-150
	nformed Consent	13		